VNRX, US9286612067

Nasdaq cuts target for VolitionRx stock to USD 13.89 from USD 16.83

Published on 10/21/2026 at 06:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 398,000 versus USD 492,323 expected. VolitionRx stock target stands at USD 13.89 after a 17.44 percent cut.

Target revision and operating figures

On October 2, 2026, Nasdaq reported a cut in the average target from USD 16.83 to USD 13.89.
VolitionRx reported USD 398,000 in second-quarter 2026 revenue against USD 492,323 expected.
VolitionRx is scheduled to report its next quarterly results on November 12, 2026.

VNRX, US9286612067, Illustration mit AI erstellt.

VolitionRx Limited (ISIN US9286612067) faced a lower analyst target after the average one-year estimate fell from USD 16.83 to USD 13.89 on October 2, 2026. Nasdaq reported the 17.44 percent reduction, extending a sequence of lower consensus targets.

Target expectations move lower

The revision followed earlier mean targets of USD 17.31 on August 4, 2026, USD 16.90 on August 28, 2026, and USD 16.83 on September 15, 2026. The latest figure therefore sits USD 2.94 below the September 15 estimate, while the source listed a target range from USD 2.02 to USD 25.20.

The target change matters because VolitionRx remains a development-stage diagnostics company. Its platform is designed to support blood-based testing for cancer and diseases associated with NETosis, according to the company's investor-relations page at VolitionRx.

What did the second quarter deliver?

For the second quarter ended June 30, 2026, revenue was USD 398,000, below the USD 492,323 consensus estimate, while reported earnings per share were minus USD 0.85 against an estimate of minus USD 0.5855, according to Nasdaq. The revenue shortfall was USD 94,323, or 19.16 percent.

Volition also presented its Nu.Q H3.1 immunoassay on October 1, 2026. The product measures nucleosomes containing histone H3.1 and is positioned for research into cell death in cancer, sepsis and other diseases, according to Volition.

Next reporting date is November 12

The next quarterly results are scheduled for November 12, 2026, according to Financhill. That report will give investors a fresh test of revenue conversion and cash needs after the second-quarter operating loss reached USD 7.33 million.

Company profile and market value

VolitionRx develops epigenetics-based blood tests through products including Nu.Q Vet, Nu.Q Discover and Nu.Q NETs. Market capitalization stood at USD 2.4 million on October 19, 2026, while the 52-week range was USD 0.17 to USD 9.60. The latest reported quarter ended June 30, 2026, with cash of USD 2.8 million.